Interaction of the novel anthracycline antitumor agent N-benzyladriamycin- 14-valerate with the C1-regulatory domain of protein kinase C: Structural requirements, isoform specificity, and correlation with drug cytotoxicity

Molecular Cancer Therapeutics

Volumn 1, Issue 7, 2002, Pages 483-492

  Roaten, J Brent ^a   Kazanietz, Marcelo G ^b   Caloca, Maria Jose ^b   Bertics, Paul J ^c   Lothstein, Leonard ^a   Parrill, Abby L ^d   Israel, Mervyn ^a   Sweatman, Trevor W ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d University of Memphis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG DERIVATIVE; ISOPROTEIN; N BENZYLDOXORUBICIN 14 VALERATE; N-BENZYLADRIAMYCIN-14-VALERATE; PROTEIN KINASE C; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BRAIN; CELL STRAIN 3T3; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; KINETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; RAT; SEQUENCE HOMOLOGY;

3T3 CELLS; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; KINETICS; MICE; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN KINASE C; PROTEIN STRUCTURE, TERTIARY; RATS; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0036561858     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Riggs, C. E. Antitumor antibiotics and related compounds. In: M. C. Perry (ed.), The Chemotherapy Source Book, Ed. 2, pp. 345-386. Baltimore: Williams and Wilkins, 1996.
2. Myers, C. E., and Chabner, B. A. In: B. A. Chabner and J. M. Collins (eds.), Anthracyclines, in Cancer Chemotherapy: Principles and Practice, pp. 356-381. Philadelphia: Lipincott, 1990.
3. Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 57: 727-741, 1999. (Pubitemid 29094544)
4. Sweatman, T. W., and Israel, M. Anthracyclines. In: B. A. Teicher (ed.), Cancer Therapeutics: Experimental and Clinical Agents, pp. 113-135. Totowa: Humana Press, Inc., 1997.
5. Medical Letter. March 26, 1999 (1049), p. 32.
6. Israel, M., Seshadri, R., Koseki, Y., and Idriss, J. M. Amelioration of adriamycin toxicity through modification of drug-DNA binding properties. Cancer Treat. Rev., 14: 163-167, 1987. (Pubitemid 18065014)
7. Sweatman, T. W., Israel, M., Koseki, Y., Seshadri, R., and Beck, W. T. Cytotoxicity and cellular pharmacology of N-benzyladriamycin-14-valerate in mechanistically different multidrug-resistant human leukemia cells. J. Cell Pharmacol., 1: 95-102, 1990.
8. Lothstein, L., Wright, H., Sweatman, T. W., and Israel, M. N-Benzy-ladriamycin-14-valerate and drug resistance: correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells. Oncol. Res., 4: 341-347, 1992. (Pubitemid 23167118)
9. Harstrick, A., Vahnhoefer, U., Schleucher, N., Schroeder, J., Baumgart, J., Scheulen, M. E., Wilke, H., and Seeber, S. (1995) Activity of N-benzy-ladriamycin-14-valerate (AD 198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines. Anticancer Drugs, 6: 681-685, 1995.
10. Mellor, H., and Parker, P. J. The extended protein kinase C superfamily. Biochem. J., 332: 281-292, 1998. (Pubitemid 28271856)
11. Nishizuka, Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J., 9: 484-496, 1995.
12. Caponigro, F., French, R. C., and Kaye, S. B. Protein kinase C: a worth while target for anticancer drugs?. Anticancer Drugs, 8: 26-33, 1997. (Pubitemid 27064746)
13. Hoffman, J. The potential for isozyme-selective modulation of protein kinase C. FASEB J., 11: 646-669, 1997.
14. Chuang, L. F., Kung, H. F., Israel, M., and Chuang, R. Y. Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoracetyladriamycin-14-valerate. Biochem. Pharmacol., 43: 865-872, 1992.
15. Wang, S., Zaharevitz, D. W., Sharma, R., Marquez, V. E., Lewin, N. E., Du, L., Blumberg, P. M., and Milne, G. W. A. The discovery of novel, structurally diverse protein kinase agonists through computer 3D-database pharmacophore search. Molecular modeling studies. J. Med. Chem., 37: 4479-4489, 1994.
16. Roaten, J. B., Kazanietz, M. G., Sweatman, T. W., Lothstein, L., and Parril, A. Molecular models of N-benzyladriamycin-14-valerate in complex with the C1-domain of protein kinase C-δ. J. Med. Chem., 44: 1028-1034, 2001. (Pubitemid 32852129)
17. Israel, M., and Seshadri, R. US Patent 4, 610,977. Washington DC: US Patent Office, 1986.
18. Lothstein, L., Rodrigues, P. J., Sweatman, T. W., and Israel, M. Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14- valerate (AD 198) are modulated by changes in 14-O-Acyl chain length. Anticancer Drugs, 9: 58-66, 1998. (Pubitemid 28088180)
19. Leventhal, P. S., and Bertics, P. J. Activation of protein kinase C by selective binding of arginine-rich polypeptides. J. Biol. Chem., 268: 13906-13913, 1993. (Pubitemid 23195503)
20. Mosior, M., and Epand, R. M. Mechanism of activation of protein kinase C: roles of diolein and phosphatidylserine. Biochemistry, 32: 66-75, 1993. (Pubitemid 23033321)
21. Kazanietz, M. G., Wang, S., Milne, G. W., Lewin, N. E., Liu, H. L., and Blumberg, P. M. Residues in the second cysteine-rich region of protein kinase-δ relevant to phorbol ester binding as revealed by site-directed mutagenesis. J. Biol. Chem., 270: 21852-21859, 1995.
22. Caloca, M. J., Fernandez, N., Lewin, N. E., Ching, D., Modali, R., Blumberg, P. M., and Kazanietz, M. G. β2-Chimaerin is a high affinity receptor for the phorbol ester tumor promoters. J. Biol. Chem., 272: 26488-26496, 1997. (Pubitemid 27458868)
23. Goodnight, J., Kazanietz, M. G., Blumberg, P. M., Mushinski, J. F., and Mischak, H. The cDNA sequence, expression pattern and protein characteristics of mouse protein kinase c-ζ. Gene, 122: 305-311, 1992. (Pubitemid 23030335)
24. Kazanietz, M. G., Areces, L. B., Bahador, A., Mischak, H., Goodnight, J., Mushinski, J. F., and Blumberg, P. M. Characterization of ligand specificity and substrate specificity for the calcium-dependent and calcium-independent protein kinase c isozymes. Mol. Pharmacol., 44: 298-307, 1993. (Pubitemid 23252234)
25. Kazanietz, M. G., Krausz, K. W., and Blumberg, P. M. Differential irreversible insertion of protein kinase c into phospholipid vesicles by phorbol esters and related activators. J. Biol. Chem., 267: 20878-20886, 1992.
26. 3H]phorbol-12, 13-dibutyrate binding. Cancer Res., 45: 19-24, 1985.
27. Sweatman, T. W., Seshadri, R., and Israel, M. Pharmacology of N-benzyladriamycin-14-valerate in the rat. Cancer Chemother. Pharmacol., 43: 419-426, 1999. (Pubitemid 29120254)
28. Mosior, M., and McLaughlin, S. Electrostatics and dimensionality can produce apparent cooperativity when protein kinase c and its substrates bind to acidic lipids in membranes. In: J. F. Kuo (ed.), Protein Kinase C. New York: Oxford University Press, 1994.
29. Carman, G. M., Deems, R. A., and Dennis, E. A. Lipid signaling enzymes and surface dilution kinetics. J. Biol. Chem., 270: 18711-18714, 1995.
30. Nadatake, T., Jeng, A. Y., and Blumberg, P. M. Comparison of protein kinase c functional assays to clarify mechanisms of inhibitor action. Biochem. Pharmacol., 37: 1541-1545, 1988. (Pubitemid 18093348)
31. Newton, A. C. Regulation of protein kinase C. Curr. Opin. Cell Biol., 9: 161-167, 1997. (Pubitemid 27135982)
32. Quest, A. F., Bardes, E. S., and Bell, R. M. A phorbol ester binding domain of protein kinase c γ. Deletion analysis of the cys2 domain defines a minimal 43-amino acid peptide. J. Biol. Chem., 269: 2961-2970, 1994.
33. Hurley, J. H., Newton, A. C., Parker, P. J., Blumberg, P. M., and Nishizuka, Y. Taxonomy and function of C1 protein kinase C homology domains. Protein Sci., 6: 477-480, 1997. (Pubitemid 27079944)
34. Palayoor, S. T., Stein, J. M., and Hait, W. N. Inhibition of protein kinase C by antineoplastic agents: implications for drug resistance. Biochem. Biophys. Res. Commun., 148: 718-725, 1987. (Pubitemid 17155474)
35. Wise, B. C., and Kuo, J. F. The modes of inhibition of acyl carnitines, adriamycin, and trifluorperazine of cardiac phospholipid-sensitive calcium-dependent protein kinase. Biochem. Pharmacol., 32: 1259-1265, 1983. (Pubitemid 13135638)
36. Hannun, Y. A., Foglesong, R. J., and Bell, R. M. The adriamycin-iron (III) complex is a potent inhibitor of protein kinase C. J. Biol. Chem., 264: 9960-9966, 1989. (Pubitemid 19159264)
37. Constantinides, P. P., Ghosaini, L., Inouchi, N., Kitamura, S., Seshadri, R., Israel, M., Sartorelli, A. C., and Sturtevant, J. M. Interaction of N-alkylanthracyclines with lipid bilayers: correlations between partition coefficients, lipid phase distributions and thermotropic behavior. Chem. Phys. Lipids, 51: 105-118, 1989. (Pubitemid 19268495)
38. Barrett, C. M., Lewis, F. L., Roaten, J. B., Sweatman, T. W., Israel, M., Cleveland, J. L., and Lothstein, L. Novel extranuclear-targeted anthracyclines override the anti-apoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol. Cancer Ther., 1: 469-481, 2002.
39. Zhang, G., Kazanietz, M. G., Blumberg, P. M., and Hurley, J. H. Crystal structure of the cys2 activator-binding domain of protein kinase C-δ in complex with phorbol ester. Cell, 81: 917-924, 1995.
40. Hurley, J. H., and Grobler, J. A. Protein kinase C and phospholipase C: bilayer interactions and regulation. Curr. Opin. Struct. Biol., 7: 557-565, 1997. (Pubitemid 27371303)
41. Hannun, Y. A., Loomis, C. R., Merrill, A. H., and Bell, R. M. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem., 261: 12604-12609, 1986. (Pubitemid 17213985)
42. Areces, L. B., Kazanietz, M. G., and Blumberg, P. M. Close similarity of baculovirus-expressed n-chimaerin and protein kinase-Cα as phorbol ester receptors. J. Biol. Chem., 269: 19553-19558, 1994. (Pubitemid 24233485)
43. Barrett, C. M., Roaten, J. B., Sweatman, T. W., Israel, M., Cleveland, J. L., Steiner, M. S., and Lothstein, L. Drug-induced modulation of protein kinase C (PKC) correlates with circumvention of Bcl-2 mediated inhibition of apoptosis. Proc. Am. Assoc. Cancer Res., 41: 822, 2000.
44. Koseki, Y., Sweatman, T. W., Savranskaya, L., and Israel, M. Potentiation of drug cytotoxicity in vitro with N-benzyladriamycin-14-valerate (AD 198). Proc. Am. Assoc. Cancer Res., 37: 334, 1996.
45. Roaten, J. B. Characterization of the phorbol ester binding C1- domain of protein kinase C as molecular target for n-benzyladriamycin-14-valerate (AD 198). Doctoral Dissertation, University of Tennessee College of Medicine, Memphis TN, 2001.
46. Tang, D. G., and Porter, A. T. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate, 32: 284-293, 1997. (Pubitemid 27374201)